Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
– Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study – Chicago, Nov. 10, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company founded by Paragon Biosciences to develop treatments for central nervous system … Read more